Biotechnology, Therapy, Medicine, RNA interference, Gene therapy, Gene

Ex-Biogen chief and Editas chair Mullen becomes CRISPR biotech's new CEO amid C-suite shake-up

On Feb 8, 2021
@FierceBiotech shared
Mullen, who will also remain as Editas’ chairman, is parachuted in as Collins leaves next week, coming off some big roles, including as Biogen’s former CEO https://t.co/070kNolis4
Open

Cynthia Collins is out as Editas Medicine’s CEO as chairman James Mullen takes over from Feb. 15 after the biotech lost its Allergan/AbbVie partnership on its leading eye disease drug EDIT-101.

www.fiercebiotech.com
On Feb 8, 2021
@FierceBiotech shared
Mullen, who will also remain as Editas’ chairman, is parachuted in as Collins leaves next week, coming off some big roles, including as Biogen’s former CEO https://t.co/070kNolis4
Open

Ex-Biogen chief and Editas chair Mullen becomes CRISPR biotech's new CEO amid C-suite shake-up

Ex-Biogen chief and Editas chair Mullen becomes CRISPR biotech's new CEO amid C-suite shake-up

Cynthia Collins is out as Editas Medicine’s CEO as chairman James Mullen takes over from Feb. 15 after the biotech lost its Allergan/AbbVie partnership on its leading eye disease drug ...

Editas, Allergan open first trial of in vivo CRISPR therapy

Editas, Allergan open first trial of in vivo CRISPR therapy

One of the four sites of the trial, in a rare form of inherited blindness, is currently listed as open for enrollment, and the companies plan to dose the first patient soon.

Editas, AbbVie rework gene editing deal as pioneering CRISPR trial resumes

Editas, AbbVie rework gene editing deal as pioneering CRISPR trial resumes

Development of EDIT-101, the first CRISPR-based therapy to be used in a company-led trial to alter genes within a person's body, will now move forward under Editas' sole ownership.

Overview: CRISPR Technology Headed to Clinical Trials

Overview: CRISPR Technology Headed to Clinical Trials

Although much of the recent attention to CRISPR gene editing has been negative, CRISPR still remains one of the great hopes for treating diseases.

Vertex Grows Gene Editing Presence, Acquiring Exonics and Expanding CRISPR Therapeutics Collaboration

Vertex Grows Gene Editing Presence, Acquiring Exonics and Expanding CRISPR Therapeutics Collaboration

Vertex Pharmaceuticals will carry out a potentially $2 billion expansion of its presence in gene editing through a pair of deals intended to enable the company to develop novel treatments ...

Backed by a $200M investment from a Korean conglomerate, Vivek Ramaswamy has quietly built a ‘mother ship’ for vant creation — with a whole new strategy in mind

Backed by a $200M investment from a Korean conglomerate, Vivek Ramaswamy has quietly built a ‘mother ship’ for vant creation — with a whole new strategy in mind

Vivek Ramaswamy built Roivant as the mother ship to a fleet of vants that were largely launched through in-licensing deals — often with the Big Pharma crowd as they winnowed out their ...

CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019

CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019

CRISPR, capacity, and consolidation powered the cell and gene therapy space in 2019, but a proactive focus on patient access topped Falcon Therapeutics

Top 10 advanced therapy milestones of 2019: Patient access takes center stage

Top 10 advanced therapy milestones of 2019: Patient access takes center stage

CRISPR, capacity, and consolidation powered the cell and gene therapy space in 2019, but a proactive focus on patient access topped the annual roundup

Aruvant to Participate in SVB Leerink's Biopharma Private Company Connect December 15 to 17

Aruvant to Participate in SVB Leerink's Biopharma Private Company Connect December 15 to 17

NEW YORK and BASEL, Switzerland, Dec. 1, 2020 /PRNewswire/ -- Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies ...

Why Editas Medicine Stock Is Skyrocketing Today

Why Editas Medicine Stock Is Skyrocketing Today

Here are some best guesses about the biotech stock's huge jump.

CRISPR enters its first human clinical trials

CRISPR enters its first human clinical trials

The gene editor will be used in lab dishes in cancer and blood disorder trials, and to directly edit a gene in human eyes in a blindness therapy test.

Despite Controversy, Human Studies of CRISPR Move Forward in the U.S.

Despite Controversy, Human Studies of CRISPR Move Forward in the U.S.

The technology that produced a global scandal in China last year has entered into clinical trials to treat sickle cell anemia and an eye disease

Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics

Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics

The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.

Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer

Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer

Cindy Collins to Step Down Effective February 15, 2021 CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today ...

Doctors use CRISPR gene editing inside a person's body for first time

Doctors use CRISPR gene editing inside a person's body for first time

The tool was used in an attempt to treat a patient's blindness. It may take up to a month to see if it worked.